Caribou Biosciences (CRBU) Asset Writedowns and Impairment (2025)
Caribou Biosciences (CRBU) reported Asset Writedowns and Impairment of $2.2 million for Q2 2025, down 76.09% on a QoQ basis from $9.2 million in Q1 2025.
Caribou Biosciences (CRBU) has 1 years of Asset Writedowns and Impairment data on file, last reported at $2.2 million in Q2 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $2.2 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (changed N/A YoY) and the FY2025 annual result came in at $12.1 million, changed N/A from the prior year.
- Asset Writedowns and Impairment retreated to $2.2 million in Q2 2025 per CRBU's latest filing, from $9.2 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $9.2 million in Q1 2025 and bottomed at $2.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Mar 31, 2025 | 9.20 Mn |